Study of late conversion from antimetabolites with standard exposure calcineurin inhibitors (CNIs) to everolimus with CNI minimization in stable kidney transplant recipients with good graft function.
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2016 New trial record